ACD's RNAscope®in situ HybridizationTechnology Gains Significant Traction

HAYWARD, California, July 15, 2014 /PRNewswire/ --

Advanced Cell Diagnostics Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, announces that its RNAscope^® RNA in situ hybridization technology has reached two major milestones. In just three years, over 100 peer-reviewed papers featuring the technology have been published, and with the significant increase in use of RNAscope, ACD has built a library of over 4000 target probes for numerous species. Probes are designed to order in under two weeks, and in just six months the library has grown by over 1500, reflecting the wide interest in ACD's breakthrough technology.

RNAscope's ability to unlock the potential of RNA biomarkers, and highly sensitive and easy technology, has resulted in its wide use throughout academia and industry, and rapidly growing body of publications. Averaging over 6 papers/month published in 2014 - a rate doubling every year - papers range from basic research in developmental biology, neuroscience and stem cells to clinical research eg cancer biomarkers, infectious diseases and ophthalmology.

Localizing and quantifying RNA sequences in the context of cells and tissues is a fundamental approach in molecular biology. RNAscope makes it accessible to researchers of any level of experience, as Alexey Pronin, PhD of the University of Miami School of Medicine, who recently published in PLoS One, explained. "Even though I had no previous experience of in situ hybridization, the RNAscope assay was easy to perform and worked first time, allowing us to confirm the expression of three different genes in the mouse eye that we had previously identified via transcriptomics. Importantly, the multiplex assay showed that two of the genes are expressed in two separate cell layers of the eye blood vessels - information that would be hard to get using other technologies."

"Publications from our customers are particularly exciting, as it shows the growing validation and adoption of our technologies at the forefront of scientific research", said Xiao-Jun Ma, ACD's CSO. "And with our probe catalog growing by 240% in the last year, targeting more than 4,000 genes in many species, it's a real testament to our fast probe development times and the scalability of our platform."

SOURCE Advanced Cell Diagnostics Inc. (ACD)

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED